Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial

被引:105
作者
Hersey, P
Coates, AS
McCarthy, WH
Thompson, JF
Sillar, RW
McLeod, R
Gill, PG
Coventry, BJ
McMullen, A
Dillon, H
Simes, RJ
机构
[1] Univ Sydney, Sydney Melanoma Unit, Sydney, NSW 2006, Australia
[2] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[3] Canc Council Australia, Sydney, NSW, Australia
[4] Newcastle Mater Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
[5] Newcastle Mater Hosp, Newcastle Melanoma Unit, Newcastle, NSW, Australia
[6] Natl Hlth & Med Res Council Trails Ctr, Camperdown, NSW, Australia
[7] Princess Alexandra Hosp, Melanoma Project, Brisbane, Qld 4102, Australia
[8] Univ Adelaide, Adelaide Melanoma Unit, Adelaide, SA, Australia
[9] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
关键词
D O I
10.1200/JCO.2002.12.094
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : Patients with high-risk melanoma treated by immunotherapy with vaccinia viral lysates were found in phase II studies to have improved survival compared with historical controls. We therefore elected to test this therapy in a phase III study. Patients and Methods: A prospective, randomized, multicenter trial to determine whether immunotherapy with a vaccine prepared from vaccinia melanoma cell lysates (VMCL) over a 2-year period after definitive surgery would improve relapse-free survival (RFS) and overall survival (OS) in patients with American Joint Committee on Cancer stage IIIB and III melanoma compared with a control group treated only with surgery. Results: A total of 700 patients were randomized: 353 to VMCL and 347 to no immunotherapy. Seventy-seven percent had lymph node (LN) metastases and 66% had clinically detected LN metastases. Analysis on the basis of all eligible, randomized patients (n = 675) found, after a median follow-up period of 8 years, a median OS of 88 months in the control versus 151 months in the treated group (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.64 to 1.02; P =.068 by stratified univariate Cox analysis). At 5 and 10 years, survival rates for control and treated patients were 54.8% v 60.6% and 41% v 53.4%, respectively. Median RFS was 43 months in the control group compared with 83 months in the treated group (HR, 0.86; 95% CI, 0.7 to 1.07; P =.17). RFS at 5 years was 50.9% for the treated group and 46.8% for the control group. There were no selective benefits from the vaccine for particular subsets of patients. Conclusion: Immunotherapy with VMCL was not associated with a statistically significant improvement in OS or RFS, with CIs not ruling out important gains from such treatment.
引用
收藏
页码:4181 / 4190
页数:10
相关论文
共 42 条
  • [1] Austin F C, 1979, Adv Cancer Res, V30, P301, DOI 10.1016/S0065-230X(08)60900-8
  • [2] A MULTIFACTORIAL ANALYSIS OF MELANOMA .3. PROGNOSTIC FACTORS IN MELANOMA PATIENTS WITH LYMPH-NODE METASTASES (STAGE-II)
    BALCH, CM
    SOONG, SJ
    MURAD, TM
    INGALLS, AL
    MADDOX, WA
    [J]. ANNALS OF SURGERY, 1981, 193 (03) : 377 - 388
  • [3] BALCH CM, 1985, ANAL PROGNOSTIC FACT, P338
  • [4] BERD D, 1986, CANCER RES, V46, P2572
  • [5] INFLAMMATORY CELL INFILTRATES IN HUMAN-MELANOMA AT DIFFERENT STAGES OF TUMOR PROGRESSION
    BROCKER, EB
    ZWADLO, G
    HOLZMANN, B
    MACHER, E
    SORG, C
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (04) : 562 - 567
  • [6] Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial
    Cascinelli, N
    Morabito, A
    Santinami, M
    MacKie, RM
    Belli, F
    [J]. LANCET, 1998, 351 (9105) : 793 - 796
  • [7] PROGNOSIS OF SKIN MELANOMA WITH REGIONAL NODE METASTASES (STAGE-II)
    CASCINELLI, N
    VAGLINI, M
    NAVA, M
    SANTINAMI, M
    MAROLDA, R
    ROVINI, D
    CLEMENTE, C
    BUFALINO, R
    MORABITO, A
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1984, 25 (04) : 240 - 247
  • [8] RESULTS OF ADJUVANT INTERFERON STUDY IN WHO MELANOMA PROGRAM
    CASCINELLI, N
    BUFALINO, R
    MORABITO, A
    MACKIE, R
    [J]. LANCET, 1994, 343 (8902) : 913 - 914
  • [9] Cascinelli N, 1995, P AN M AM SOC CLIN, V14, P410
  • [10] CASSEL WA, 1983, CANCER, V52, P856, DOI 10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO